Literature DB >> 21129063

Molecular diagnostics in embryonal brain tumors.

Charles G Eberhart1.   

Abstract

Embryonal brain tumors are a heterogeneous group of neoplasms united by the presence of poorly differentiated stem-like cells. Molecular details are increasingly being used to separate them into biologically and clinically meaningful groups. For medulloblastoma, integrated mRNA expression profiling and DNA analysis by a number of research groups defines 4-6 distinctive molecular variants. A subset with prominent Wnt activity is associated with good clinical outcomes and classic histology. Medulloblastomas showing a Hedgehog gene expression signature are frequently of the desmoplastic/nodular subtype. Interestingly, Hedgehog activity is found in tumors arising either in infants or older teenagers and adults. The association of clinically aggressive medulloblastoma with MYC expression, large cell/anaplastic change and high levels of photoreceptor differentiation transcripts has also been noted in several studies. Immunohistochemical analysis of just one or two genes per molecular medulloblastoma variant may be sufficient for accurate classification, and this would be of great practical utility if validated. Advances have also been made in the classification of central nervous system (CNS) Primitive Neuroectodermal Tumors (PNET), as several groups have identified an amplicon at chromosome 19q13.41-42, which appears to define a unique PNET subtype associated with prominent true rosettes, young age and very poor outcomes.
© 2010 The Author; Brain Pathology © 2010 International Society of Neuropathology.

Entities:  

Mesh:

Year:  2011        PMID: 21129063      PMCID: PMC3575597          DOI: 10.1111/j.1750-3639.2010.00455.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  77 in total

1.  Prediction of central nervous system embryonal tumour outcome based on gene expression.

Authors:  Scott L Pomeroy; Pablo Tamayo; Michelle Gaasenbeek; Lisa M Sturla; Michael Angelo; Margaret E McLaughlin; John Y H Kim; Liliana C Goumnerova; Peter M Black; Ching Lau; Jeffrey C Allen; David Zagzag; James M Olson; Tom Curran; Cynthia Wetmore; Jaclyn A Biegel; Tomaso Poggio; Shayan Mukherjee; Ryan Rifkin; Andrea Califano; Gustavo Stolovitzky; David N Louis; Jill P Mesirov; Eric S Lander; Todd R Golub
Journal:  Nature       Date:  2002-01-24       Impact factor: 49.962

2.  Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors.

Authors:  R T Woodburn; B Azzarelli; J F Montebello; I E Goss
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

3.  Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease.

Authors:  T J MacDonald; K M Brown; B LaFleur; K Peterson; C Lawlor; Y Chen; R J Packer; P Cogen; D A Stephan
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

4.  MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group.

Authors:  Naji Aldosari; Sandra H Bigner; Peter C Burger; Laurence Becker; James L Kepner; Henry S Friedman; Roger E McLendon
Journal:  Arch Pathol Lab Med       Date:  2002-05       Impact factor: 5.534

5.  C-MYC expression in medulloblastoma and its prognostic value.

Authors:  J Herms; I Neidt; B Lüscher; A Sommer; P Schürmann; T Schröder; M Bergmann; B Wilken; S Probst-Cousin; P Hernáiz-Driever; J Behnke; F Hanefeld; T Pietsch; H A Kretzschmar
Journal:  Int J Cancer       Date:  2000-09-20       Impact factor: 7.396

6.  Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas.

Authors:  Charles G Eberhart; John E Kratz; Amy Schuster; Pat Goldthwaite; Kenneth J Cohen; Elizabeth J Perlman; Peter C Burger
Journal:  Brain Pathol       Date:  2002-01       Impact factor: 6.508

7.  Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas.

Authors:  R P Dahmen; A Koch; D Denkhaus; J C Tonn; N Sörensen; F Berthold; J Behrens; W Birchmeier; O D Wiestler; T Pietsch
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

8.  Role of Wnt pathway in medulloblastoma oncogenesis.

Authors:  Naoki Yokota; Shigeru Nishizawa; Seiji Ohta; Hiroaki Date; Haruhiko Sugimura; Hiroki Namba; Masato Maekawa
Journal:  Int J Cancer       Date:  2002-09-10       Impact factor: 7.396

9.  AXIN1 mutations but not deletions in cerebellar medulloblastomas.

Authors:  Nathalie Baeza; Jun Masuoka; Paul Kleihues; Hiroko Ohgaki
Journal:  Oncogene       Date:  2003-01-30       Impact factor: 9.867

10.  Clinical and molecular stratification of disease risk in medulloblastoma.

Authors:  R Gilbertson; C Wickramasinghe; R Hernan; V Balaji; D Hunt; D Jones-Wallace; J Crolla; R Perry; J Lunec; A Pearson; D Ellison
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640

View more
  15 in total

Review 1.  Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions.

Authors:  Jon D Larson; David A Largaespada
Journal:  In Vivo       Date:  2012 Jul-Aug       Impact factor: 2.155

Review 2.  Matching mice to malignancy: molecular subgroups and models of medulloblastoma.

Authors:  Jasmine Lau; Christin Schmidt; Shirley L Markant; Michael D Taylor; Robert J Wechsler-Reya; William A Weiss
Journal:  Childs Nerv Syst       Date:  2012-04       Impact factor: 1.475

3.  Wnt activation affects proliferation, invasiveness and radiosensitivity in medulloblastoma.

Authors:  Roberta Salaroli; Alice Ronchi; Francesca Romana Buttarelli; Filippo Cortesi; Valeria Marchese; Elena Della Bella; Cristiano Renna; Caterina Baldi; Felice Giangaspero; Giovanna Cenacchi
Journal:  J Neurooncol       Date:  2014-09-28       Impact factor: 4.130

Review 4.  Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Brain Pathol       Date:  2011-07-07       Impact factor: 6.508

5.  Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct.

Authors:  Paul A Northcott; Thomas Hielscher; Adrian Dubuc; Stephen Mack; David Shih; Marc Remke; Hani Al-Halabi; Steffen Albrecht; Nada Jabado; Charles G Eberhart; Wieslawa Grajkowska; William A Weiss; Steven C Clifford; Eric Bouffet; James T Rutka; Andrey Korshunov; Stefan Pfister; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2011-06-17       Impact factor: 17.088

6.  MyoD is a tumor suppressor gene in medulloblastoma.

Authors:  Joyoti Dey; Adrian M Dubuc; Kyle D Pedro; Derek Thirstrup; Brig Mecham; Paul A Northcott; Xiaochong Wu; David Shih; Stephen J Tapscott; Michael LeBlanc; Michael D Taylor; James M Olson
Journal:  Cancer Res       Date:  2013-10-03       Impact factor: 12.701

7.  The role of CD133+ cells in a recurrent embryonal tumor with abundant neuropil and true rosettes (ETANTR).

Authors:  Shawn L Hervey-Jumper; David B Altshuler; Anthony C Wang; Xiaobing He; Cormac O Maher; Patricia L Robertson; Hugh J L Garton; Xing Fan; Karin M Muraszko; Sandra Camelo-Piragua
Journal:  Brain Pathol       Date:  2013-08-12       Impact factor: 6.508

8.  OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells.

Authors:  Ren-Yuan Bai; Verena Staedtke; Hart G Lidov; Charles G Eberhart; Gregory J Riggins
Journal:  Cancer Res       Date:  2012-09-17       Impact factor: 12.701

9.  Is there an increased risk of spinal relapse in standard-risk medulloblastoma/primitive neuroectodermal tumor patients who receive only a reduced dose of craniospinal radiotherapy?

Authors:  Akıncı Burcu; Çetingül Nazan; Özdemir Özgür; Kamer Serra; Kantar Mehmet; Aksoylar Serap; Demirağ Bengü; Vergin Canan; Öniz Haldun; Kansoy Savaş; Turhan Tuncer; Akalın Taner; Ertan Yeşim; Kitiş Ömer; Anacak Yavuz
Journal:  Childs Nerv Syst       Date:  2018-06-04       Impact factor: 1.475

10.  A developmental program drives aggressive embryonal brain tumors.

Authors:  Tenley C Archer; Scott L Pomeroy
Journal:  Nat Genet       Date:  2014-01       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.